On the back of the news of the HIV test funding via the Australian Government, AT1 holders should be excited on the recent LDX news.
Febridx now being distributed in AUS and NZ via Regional Health Care Group (Henry Schein subsidiary) with sales to commence immediately.
Noting that stock supplies for Febridx were built during mid/end last year for the US launch, the stock levels likely to see an increase in orders for AT1 of the pascal units.
Seems mutually beneficial to hedge investments in both companies..
AT1 Price at posting:
2.5¢ Sentiment: Buy Disclosure: Held
